drugset / Trial / NCT00372853
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.
Timeline
- Start
- 2006-11
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sunitinib | Small molecule | 37.5 mg | — |
| Subject | Sunitinib | Small molecule | 50 mg | — |
| Subject | Tremelimumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 15 mg/kg | Intravenous |